These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15728450)

  • 41. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
    Rich RF; Green WR
    J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
    Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
    J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
    Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
    J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides.
    Sauzet JP; Gras-Masse H; Guillet JG; Gomard E
    Int Immunol; 1996 Apr; 8(4):457-65. PubMed ID: 8671632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland.
    Rouvio O; Dvorkin T; Amir-Kroll H; Atias D; Cohen IR; Rager-Zisman B; Porgador A
    Vaccine; 2005 May; 23(27):3508-18. PubMed ID: 15855009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
    Ryan CM; Schell TD
    J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
    Rubinstein MP; Kadima AN; Salem ML; Nguyen CL; Gillanders WE; Cole DJ
    J Immunol; 2002 Nov; 169(9):4928-35. PubMed ID: 12391205
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
    Roth E; Pircher H
    J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice.
    Sette AD; Oseroff C; Sidney J; Alexander J; Chesnut RW; Kakimi K; Guidotti LG; Chisari FV
    J Immunol; 2001 Jan; 166(2):1389-97. PubMed ID: 11145724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.
    Coles RM; Mueller SN; Heath WR; Carbone FR; Brooks AG
    J Immunol; 2002 Jan; 168(2):834-8. PubMed ID: 11777979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
    Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
    J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The exocytosis of lytic granules is impaired in Vti1b- or Vamp8-deficient CTL leading to a reduced cytotoxic activity following antigen-specific activation.
    Dressel R; Elsner L; Novota P; Kanwar N; Fischer von Mollard G
    J Immunol; 2010 Jul; 185(2):1005-14. PubMed ID: 20543108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division.
    Oehen S; Brduscha-Riem K
    J Immunol; 1998 Nov; 161(10):5338-46. PubMed ID: 9820507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
    Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.